|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-6-11
|
|
pubmed:abstractText |
Capecitabine is an oral fluoropyrimidine with considerable activity and minimal myelosuppression and alopecia. This phase I study evaluated the addition of capecitabine to epirubicin/docetaxel combination therapy as first-line treatment for advanced breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:AngioliniCC,
pubmed-author:BaldiniAA,
pubmed-author:BergaglioMM,
pubmed-author:CanaveseGG,
pubmed-author:Del MastroLL,
pubmed-author:GarroneOO,
pubmed-author:LambiaseAA,
pubmed-author:MerlanoMM,
pubmed-author:RossiLL,
pubmed-author:TolinoGG,
pubmed-author:VenturiniMM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
546-52
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12056704-Adult,
pubmed-meshheading:12056704-Aged,
pubmed-meshheading:12056704-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12056704-Breast Neoplasms,
pubmed-meshheading:12056704-Deoxycytidine,
pubmed-meshheading:12056704-Dose-Response Relationship, Drug,
pubmed-meshheading:12056704-Epirubicin,
pubmed-meshheading:12056704-Female,
pubmed-meshheading:12056704-Fluorouracil,
pubmed-meshheading:12056704-Humans,
pubmed-meshheading:12056704-Infusions, Intravenous,
pubmed-meshheading:12056704-Middle Aged,
pubmed-meshheading:12056704-Neutropenia,
pubmed-meshheading:12056704-Paclitaxel,
pubmed-meshheading:12056704-Taxoids,
pubmed-meshheading:12056704-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
|
|
pubmed:affiliation |
Division of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy. marco.venturini@istge.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
